These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Recent advances in inhibitors of sirtuin1/2: an update and perspective. Zhou Z; Ma T; Zhu Q; Xu Y; Zha X Future Med Chem; 2018 Apr; 10(8):907-934. PubMed ID: 29642711 [TBL] [Abstract][Full Text] [Related]
25. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Huber K; Superti-Furga G Bioorg Med Chem; 2011 Jun; 19(12):3616-24. PubMed ID: 21306906 [TBL] [Abstract][Full Text] [Related]
26. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. Nayagam VM; Wang X; Tan YC; Poulsen A; Goh KC; Ng T; Wang H; Song HY; Ni B; Entzeroth M; Stünkel W J Biomol Screen; 2006 Dec; 11(8):959-67. PubMed ID: 17099246 [TBL] [Abstract][Full Text] [Related]
27. The Current State of NAD Schiedel M; Robaa D; Rumpf T; Sippl W; Jung M Med Res Rev; 2018 Jan; 38(1):147-200. PubMed ID: 28094444 [TBL] [Abstract][Full Text] [Related]
29. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013). Valente S; Mai A Expert Opin Ther Pat; 2014 Apr; 24(4):401-15. PubMed ID: 24397271 [TBL] [Abstract][Full Text] [Related]
30. Promising drug discovery strategies for sirtuin modulators: what lessons have we learnt? Garg G; Singh AK; Singh S; Rizvi SI Expert Opin Drug Discov; 2021 Aug; 16(8):915-927. PubMed ID: 33880981 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. McCarthy AR; Pirrie L; Hollick JJ; Ronseaux S; Campbell J; Higgins M; Staples OD; Tran F; Slawin AM; Lain S; Westwood NJ Bioorg Med Chem; 2012 Mar; 20(5):1779-93. PubMed ID: 22304848 [TBL] [Abstract][Full Text] [Related]
32. Benzimidazoles as new scaffold of sirtuin inhibitors: green synthesis, in vitro studies, molecular docking analysis and evaluation of their anti-cancer properties. Yoon YK; Ali MA; Wei AC; Shirazi AN; Parang K; Choon TS Eur J Med Chem; 2014 Aug; 83():448-54. PubMed ID: 24992072 [TBL] [Abstract][Full Text] [Related]
33. [Sirtuins--modulation of their activity as a novel therapeutic target]. Kucińska M; Piotrowska H; Murias M Pol Merkur Lekarski; 2010 Mar; 28(165):231-5. PubMed ID: 20815175 [TBL] [Abstract][Full Text] [Related]
35. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. Colak Y; Yesil A; Mutlu HH; Caklili OT; Ulasoglu C; Senates E; Takir M; Kostek O; Yilmaz Y; Yilmaz Enc F; Tasan G; Tuncer I J Gastrointestin Liver Dis; 2014 Sep; 23(3):311-9. PubMed ID: 25267960 [TBL] [Abstract][Full Text] [Related]
36. Sirtuins and disease: the road ahead. Carafa V; Nebbioso A; Altucci L Front Pharmacol; 2012; 3():4. PubMed ID: 22319497 [TBL] [Abstract][Full Text] [Related]
37. Small Molecules as SIRT Modulators. Bai X; Yao L; Ma X; Xu X Mini Rev Med Chem; 2018; 18(13):1151-1157. PubMed ID: 27334466 [TBL] [Abstract][Full Text] [Related]
38. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Knutson MD; Leeuwenburgh C Nutr Rev; 2008 Oct; 66(10):591-6. PubMed ID: 18826454 [TBL] [Abstract][Full Text] [Related]